Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc. (CHRS) Healthcare & Pipeline Overview

Coherus Oncology, Inc. is a leading biopharmaceutical company specializing in immunotherapies and biosimilars for cancer treatment, leveraging a robust pipeline to address critical healthcare needs in the oncology sector.

What Is the Investment Thesis for CHRS?

Coherus Oncology, Inc. presents a compelling investment thesis driven by its strong product pipeline and strategic collaborations. The company’s lead product, UDENYCA, has established a significant market presence, contributing to its impressive profit margin of 398.4%. With a P/E ratio of 1.3, the stock appears undervalued relative to its growth potential. Upcoming product launches and ongoing clinical trials for therapies like LOQTORZI and Casdozokitug are expected to drive revenue growth in the coming years. The global oncology market is projected to reach $300 billion by 2026, providing a substantial opportunity for Coherus to capture market share. However, investors should remain aware of potential risks, including competition from other biosimilars and the challenges of navigating regulatory approvals.

Based on FMP financials and quantitative analysis

CHRS Key Highlights

• Market Cap of $205.04M reflects a growing interest in biopharmaceuticals.
• P/E ratio of 1.3 indicates potential undervaluation compared to industry peers.
• Profit margin of 398.4% highlights exceptional operational efficiency.
• Gross margin of 67.2% exceeds industry averages, showcasing strong pricing power.
• Beta of 1.04 suggests stock volatility is in line with the broader market.

Who Are CHRS's Competitors?

CHRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CHRS's Key Strengths?

• Diverse product pipeline with multiple biosimilars and novel therapies.
• Strong profit margins reflecting operational efficiency.
• Strategic partnerships enhancing development and commercialization capabilities.
• Established market presence with recognized products like UDENYCA.

What Are CHRS's Weaknesses?

• Dependence on a limited number of products for revenue generation.
• Potential challenges in navigating regulatory approvals for new therapies.
• The competitive landscape may pressure pricing and market share.
• Limited brand recognition compared to larger pharmaceutical companies.

What Could Drive CHRS Stock Higher?

• Clinical trial results for LOQTORZI expected in Q3 2026.
• Expansion of UDENYCA distribution channels across the U.S.
• Anticipated launch of Casdozokitug in late 2026.
• Collaboration with Junshi Biosciences for toripalimab development.
• Regulatory submissions for new biosimilars planned for 2026.

What Are the Key Risks for CHRS?

• Financial-distress signal — its Altman Z-Score of -8.43 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Increased competition from new entrants in the biosimilars market.
• Regulatory hurdles that could delay product approvals.
• Market volatility impacting funding for R&D initiatives.
• Patent expirations leading to potential revenue loss from existing products.

What Are the Growth Opportunities for CHRS?

• Expansion of UDENYCA: UDENYCA, a biosimilar to Neulasta, has already gained traction in the market, with the global biosimilar market projected to reach $100 billion by 2025. Coherus aims to leverage this growth by increasing market penetration and expanding its distribution channels, potentially leading to significant revenue growth over the next few years.
• Advancements in LOQTORZI: The development of LOQTORZI, a next-generation PD-1 inhibitor, could position Coherus as a key player in the immunotherapy space. With a growing market for PD-1 inhibitors expected to reach $50 billion by 2026, successful clinical trials and subsequent approvals could drive substantial revenue for the company.
• Collaboration with Junshi Biosciences: The partnership with Junshi Biosciences for the co-development of toripalimab offers Coherus access to innovative therapies and shared expertise. This collaboration could expedite the development process and enhance the company’s portfolio, tapping into the growing demand for advanced cancer treatments.
• Biosimilars for inflammatory diseases: The introduction of YUSIMRY, a biosimilar to Humira, positions Coherus to capitalize on the expanding market for biosimilars in inflammatory diseases. With the global biosimilar market projected to grow significantly, YUSIMRY could provide a steady revenue stream as it gains acceptance among healthcare providers.
• Emerging therapies in clinical trials: Coherus is actively developing several investigational therapies, including CHS-114 and CHS-1000. As these therapies progress through clinical trials, successful outcomes could lead to new product launches, further diversifying the company’s revenue streams and enhancing its competitive position in the oncology market.

What Opportunities Does CHRS Have?

• Growing demand for biosimilars as healthcare costs rise.
• Expansion into new therapeutic areas and geographic markets.
• Advancements in immunotherapy present new product development opportunities.
• Collaboration with other biotech firms could enhance innovation.

What Threats Does CHRS Face?

• Intense competition from established pharmaceutical and biotech companies.
• Regulatory changes could impact product approvals and market access.
• Patent expirations may lead to increased competition from generics.
• Market volatility could affect funding and investment in R&D.

What Are CHRS's Competitive Advantages?

• Strong pipeline of innovative therapies differentiates Coherus in the market.
• Established partnerships with leading biotechnology firms enhance development capabilities.
• Expertise in biosimilars provides a competitive edge in pricing and access.
• Significant profit margins indicate operational efficiency and pricing power.
• Focus on oncology positions the company in a high-growth market segment.

What Does CHRS Do?

Founded in 2010 and headquartered in Redwood City, California, Coherus Oncology, Inc. is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative immunotherapies for cancer treatment. Initially known as Coherus BioSciences, Inc., the company rebranded to Coherus Oncology, Inc. in May 2025 to better reflect its focus on oncology. Coherus has developed a diverse portfolio of products, including UDENYCA, a biosimilar to Neulasta, which serves as a long-acting granulocyte-colony stimulating factor, and LOQTORZI, a next-generation programmed death receptor-1 inhibitor. The company is also advancing several investigational therapies, such as Casdozokitug, a monoclonal antibody targeting interleukin 27, and CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody. Additionally, Coherus offers YUSIMRY, a biosimilar to Humira, and CIMERLI, a Lucentis biosimilar. The company has established strategic collaborations with Junshi Biosciences and various license agreements with notable entities like Genentech, Inc. and Novartis Institutes for Biomedical Research, enhancing its development capabilities and market reach. Coherus’s commitment to innovation and strategic partnerships positions it well within the competitive landscape of oncology therapeutics.

What Products and Services Does CHRS Offer?

• Research and develop immunotherapies for cancer treatment.
• Commercialize biosimilars to improve patient access to essential therapies.
• Collaborate with global partners to enhance product development.
• Focus on innovative monoclonal antibodies targeting specific cancer pathways.
• Provide cost-effective alternatives to existing cancer treatments.
• Engage in clinical trials to validate the efficacy of new therapies.

How Does CHRS Make Money?

• Generate revenue through the sale of biosimilars and proprietary therapies.
• Leverage strategic partnerships for co-development and commercialization.
• Utilize research and development to innovate and expand the product pipeline.
• Focus on regulatory approvals to bring new therapies to market.
• Engage in licensing agreements to enhance product offerings.

What Industry Does CHRS Operate In?

The biotechnology industry, particularly in oncology, is experiencing rapid growth, driven by advancements in immunotherapy and personalized medicine. The global oncology therapeutics market is expected to grow at a CAGR of 10.2%, reaching $300 billion by 2026. Coherus Oncology, Inc. operates in a competitive landscape with established players like Amgen and Mylan, but its focus on biosimilars and innovative therapies positions it favorably. The increasing demand for cost-effective cancer treatments presents significant opportunities for Coherus to expand its market presence.

Who Are CHRS's Key Customers?

• Healthcare providers and hospitals seeking effective cancer treatments.
• Pharmaceutical distributors and wholesalers for product distribution.
• Patients requiring access to biosimilars and innovative therapies.
• Payers and insurance companies looking for cost-effective treatment options.
• Collaborative partners in research and development initiatives.

FY2026 estForward Outlook

Wall Street analysts project Coherus Oncology, Inc. revenue of about $61.6M for fiscal 2026, with EPS near $-1.01. The estimate reflects 5 contributing analysts.

F-Score 3/9Financial Health

Coherus Oncology, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.43 places it in the distress zone, a signal of elevated financial risk.

P/E 1.3Key Financial Metrics

Return on assets is -57.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -98.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -78.3%, the inverse of the P/E and a quick read on earnings relative to price.

Coherus Oncology, Inc. (CHRS) Valuation Context

Valued at $205.04M, CHRS is classified as a micro-cap stock. Relative to its peer group, CHRS's quantitative score of 11/100 is below the peer average of 84/100.

CHRS Revenue & Earnings Trend

In Q1 2026, CHRS generated $12.3M in top-line revenue, marking a sequential decrease of 3.4%. The company recorded a net loss of $37.9M, with diluted EPS of $-0.28. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CHRS averaged $-0.32 in diluted EPS.

Company Profile

Coherus Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Dennis Lanfear. CHRS has traded publicly since 2014.

CHRS Financials

CHRS Latest News

CHRS Analyst Consensus

CHRS MoonshotScore

Common Questions About CHRS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources